STOCK TITAN

Haemonetics Corporation (HAE) Stock Price, News & Analysis

HAE NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
13 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+17.5% close of October 8, 2026
1-year change
+60% closing prices, November 20, 2025 to November 20, 2026
1-month change
+1.6% closing prices, October 20, 2026 to November 20, 2026

Company Description

Haemonetics Corporation (NYSE: HAE) is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. According to the company’s own descriptions, its solutions address critical medical needs across hospital settings, plasma collection operations and blood centers. Within the broader manufacturing sector, Haemonetics is associated with surgical and medical instrument manufacturing, focusing on technologies that support blood management, plasma collection and related clinical workflows.

Haemonetics states that its offerings include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients. In addition, the company provides end-to-end plasma collection technologies that are intended to optimize operations for plasma centers. Haemonetics also supplies products that enable blood centers to collect in-demand blood components, aligning with its historical focus on blood and plasma systems.

Haemonetics’ activities can be viewed across three primary areas: plasma, blood centers and hospital. Haemonetics’ product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. Haemonetics supplies both consumables and devices that support blood and plasma collection and processing.

Haemonetics is incorporated in Massachusetts and lists Boston, Massachusetts as the location of its principal executive offices in recent SEC filings. Its common stock trades on the New York Stock Exchange under the ticker symbol HAE. The company regularly communicates with investors through earnings releases, conference calls and participation in healthcare investment conferences, as reflected in its press releases and Form 8-K filings.

Business segments and focus areas

Haemonetics operates under three segments: plasma, blood center and hospital. The company emphasizes its plasma and hospital segments due to their growth potential, while the blood center segment is described as facing higher competition. Across these segments, Haemonetics’ product revenue is linked to disposable blood component collection and processing sets and associated equipment.

Company press releases further describe Haemonetics as offering hospital technologies that help advance standards of care and improve outcomes, plasma collection technologies that support plasma center operations, and products that enable blood centers to collect blood components that are in demand. Together, these activities position Haemonetics as a specialist in technologies that support blood and plasma management in clinical and collection environments.

Interventional and vascular closure technologies

Haemonetics has expanded into interventional technologies through its acquisition of Vivasure Medical Limited, as disclosed in a Form 8-K filed on January 9, 2026 and in related press releases. Vivasure is described as a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Its PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures, according to the acquisition announcement.

The acquisition press release notes that adding Vivasure’s technology expands Haemonetics’ range of closure devices and bolsters its presence in the large-bore closure market. This reflects an extension of Haemonetics’ portfolio into advanced closure products that are intended to support minimally invasive cardiovascular and endovascular procedures. PerQseal and PerQseal Elite are described as not available for sale in the United States in the cited materials.

Regulatory and public company profile

Haemonetics is a publicly traded company subject to U.S. securities regulations and files reports with the Securities and Exchange Commission. Recent Form 8-K filings document events such as quarterly financial results, the acquisition of Vivasure Medical Limited and matters submitted to shareholder votes at the annual meeting. These filings confirm the company’s status as a registrant with a Commission File Number of 001-14041 and identify it as a Massachusetts corporation.

The company regularly announces the timing of its quarterly financial results and hosts conference calls and webcasts with investors and analysts to discuss those results. It also participates in healthcare conferences organized by financial institutions, as indicated by press releases describing presentations at events such as the J.P. Morgan Healthcare Conference and the Goldman Sachs Global Healthcare Conference.

Role in the medical technology and blood management space

Across its communications, Haemonetics consistently describes itself as a global medical technology company focused on addressing critical medical needs. Its activities in hospital technologies, plasma collection and blood center products align with the industry classification of surgical and medical instrument manufacturing. The emphasis on disposable collection and processing sets, related equipment and technologies for plasma centers and hospitals underscores its role in supporting blood and plasma-related procedures and operations.

The acquisition of Vivasure Medical Limited further connects Haemonetics to technologies used in structural heart and endovascular procedures, particularly in the area of large-bore vascular closure. According to the company’s press release, this acquisition is intended to expand its closure device offerings with clinically differentiated technology for arterial and venous access closure.

Stock and investor information

Haemonetics’ common stock is listed on the New York Stock Exchange under the symbol HAE. The company issues press releases to announce earnings availability, conference call details and other material events, and it furnishes these releases as exhibits to Form 8-K filings. Shareholders vote on matters such as the election of directors, advisory approval of executive compensation and the ratification of the independent registered public accounting firm, as documented in the Form 8-K reporting the results of the 2025 Annual Meeting of Shareholders.

Stock Performance

$120.16
-0.17%
-0.21
Last updated: at
+60%
Performance 1 year
45.5M
Shares outstanding As of October 30, 2026.

Haemonetics Corporation (HAE) closed at $120.16 on November 20, 2026. Over the past 12 months, the price has gained 60.0%.

See what a $1,000 investment in HAE would be worth today

Average down calculator for HAE

HAE Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Haemonetics Corporation has 10 recent news articles, with the latest published on . Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, fda approval, earnings date, management. View all HAE news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
836
Shares Sold
1
Transactions
Most Recent Transaction
Maunsell Farris Maryanne (VP, Chief Accounting Officer) sold 836 shares @ $120.99 on November 11, 2026

Insider selling at Haemonetics Corporation over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Haemonetics Corporation generated $1.3B in revenue in FY2026, retaining a 59.0% gross margin, operating income reached $156.7M (11.8% operating margin), and net income was $97.3M, reflecting a 7.3% net profit margin. Diluted earnings per share stood at $2.05. The company generated $293.2M in operating cash flow. The current ratio was 2.95, measuring current assets divided by current liabilities.

$1.3B
Revenue (FY2026)
$97.3M
Net Income (FY2026)
$293.2M
Operating Cash Flow

Upcoming Events

Q1
2027
Q1 2027 Corporate

Segment reporting change

Reporting segments reorganize: Plasma and Blood Center -> Apheresis; Hospital renamed MedSurg. Effective Q1 fiscal 2027.

Haemonetics Corporation has 1 upcoming scheduled event. The next event, "Segment reporting change", is expected in Q1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the HAE stock price.

Short Interest History

Last 12 Months

Short interest in Haemonetics Corporation (HAE) currently stands at 3.6 million shares, up 5.0% from the previous reporting period, representing 8.0% of the float.

Days to Cover History

Last 12 Months

Days to cover for Haemonetics Corporation (HAE) currently stands at 6.3 days, up 61.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 40.9%. Across the settlements charted above, it has ranged from 2.0 to 6.3 days.

HAE Company Profile & Sector Positioning

Haemonetics Corporation (HAE) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing HAE often look at related companies in the same sector, including LivaNova PLC (LIVN), Integer Holdings Corporation (ITGR), 10x Genomics, Inc. (TXG), Globus Medical Inc (GMED), and Bio-Rad Laboratories, Inc. (BIO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HAE's relative position within its industry.

Frequently Asked Questions

The current stock price of Haemonetics Corporation (HAE) is $120.16 as of November 20, 2026.

The market cap of Haemonetics Corporation (HAE) is approximately $5.5B. Learn more about what market capitalization means .

The FY2026 revenue of Haemonetics Corporation (HAE) is $1.3B, from its most recent completed fiscal year.

The FY2026 net income of Haemonetics Corporation (HAE) is $97.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Haemonetics Corporation (HAE) is $2.05 for FY2026, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Haemonetics Corporation (HAE) is $293.2M for FY2026, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Haemonetics Corporation (HAE) is 7.3% for FY2026, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Haemonetics Corporation (HAE) is 11.8% for FY2026, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Haemonetics Corporation (HAE) is 59.0% for FY2026, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Haemonetics Corporation (HAE), current assets divided by current liabilities, was 2.95 at the end of FY2026, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Haemonetics Corporation (HAE) is $787.6M for FY2026, its most recent completed fiscal year.

The operating income of Haemonetics Corporation (HAE) is $156.7M for FY2026, its most recent completed fiscal year. Learn about operating income.

Haemonetics Corporation describes itself as a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Its solutions address critical medical needs and include hospital technologies to advance standards of care, end-to-end plasma collection technologies to optimize operations for plasma centers, and products that enable blood centers to collect in-demand blood components.

Haemonetics operates in the surgical and medical instrument manufacturing industry within the broader manufacturing sector. Its activities focus on medical technologies that support hospital care, plasma collection and blood center operations.

Haemonetics operates under three segments: plasma, blood center and hospital. The company emphasizes its plasma and hospital segments due to their growth potential, while the blood center segment is described as facing higher competition.

Haemonetics’ product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. These products support blood and plasma collection and processing across its segments.

Recent SEC filings identify Haemonetics Corporation as a Massachusetts corporation with principal executive offices in Boston, Massachusetts.

Haemonetics Corporation’s common stock trades on the New York Stock Exchange under the ticker symbol HAE, as noted in multiple company press releases.

Haemonetics describes its offerings as including end-to-end plasma collection technologies designed to optimize operations for plasma centers. These technologies are part of the company’s plasma segment and support the collection of plasma for healthcare use.

The company states that it offers a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients. These technologies address critical medical needs in hospital settings.

In a Form 8-K filed on January 9, 2026 and related press releases, Haemonetics announced that it acquired Vivasure Medical Limited, a Galway, Ireland-based company focused on next-generation technology for percutaneous vessel closure. The acquisition adds Vivasure’s PerQseal Elite system, which uses a proprietary bioabsorbable patch for large-bore arterial and venous closure, expanding Haemonetics’ range of closure devices and its presence in the large-bore closure market.

Haemonetics announces the timing of its quarterly financial results in press releases and then makes the results available on its investor relations resources. It also hosts conference calls and webcasts with investors and analysts to discuss the results, and furnishes related earnings releases as exhibits to Form 8-K filings.

Recent Form 8-K filings show that Haemonetics reports material events such as the acquisition of Vivasure Medical Limited, quarterly financial results and matters submitted to shareholder votes at the annual meeting. These filings provide official regulatory disclosure of significant corporate events.